TGFB1 and diabetic kidney disease: In studies using the LLC-PK1 cell model of DKD, the protective effect of the antidiabetic drug liraglutide may be associated with the inhibition of TGF-β1, and further in vitro and in vivo studies are needed to clarify its specific mechanism of action (37).